Ocular Therapeutix Q1 net loss widens to $30.3M; DEXTENZA rev up 6% to $13.2M

OCULAR THERAPEUTIX, INC

2023-Q1 EPS reported -$0.39 revenue$13,374,000

Net loss of $30.3M ($0.39/share) vs $12.5M ($0.16/share) in Q1 2022; includes $6.6M non-cash derivative fair value charge.
DEXTENZA net product revenue $13.2M (+6% YoY); total net revenue $13.4M. FY2023 revenue guidance reiterated at $55-60M.
Cash & equivalents $79.0M at Mar 31, 2023 (down from $102.3M); cash runway to mid-2024 excluding planned OTX-TKI trials.
OTX-TKI wet AMD Phase 1 12-month data to be presented June 2023; potentially start pivotal trial in Q3 2023.
OTX-TIC glaucoma Phase 2 enrolling; top-line data expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OCULAR THERAPEUTIX, INC reported the first quarter ended March 31, 2023 results: revenue $13.2 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $13.2 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Net product revenue of DEXTENZA for the first quarter of 2023 was $13.2 million

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-057139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.